Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 05, 2019

SELL
$16.89 - $29.88 $21,957 - $38,844
-1,300 Closed
0 $0
Q2 2019

Aug 19, 2019

BUY
$18.08 - $19.83 $23,503 - $25,778
1,300 New
1,300 $25,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.52B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Griffin Asset Management, Inc. Portfolio

Follow Griffin Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Griffin Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Griffin Asset Management, Inc. with notifications on news.